Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 13/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21510777 | 0.93 | CRBN (0.53) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21510415 | 0.92 | CRBN (0.52) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21510778 | 0.90 | CRBN (0.51) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21510388 | 0.89 | CRBN (0.51) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21510416 | 0.86 | CRBN (0.47) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21493128 | 0.86 | CRBN (0.63) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21510338 | 0.83 | CRBN (0.45) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL25219152 | 0.80 | CRBN (0.66) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL27430103 | 0.80 | CRBN (0.40) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL26672025 | 0.80 | CRBN (0.55) | CRBNIKZF3DDB1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358952-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-06-14 | — | — | US | disclosed |
| US-20190322647-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322647-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | CRBN 671/4885IKZF3 3119/4885DDB1 97/4885 |
| US-11358952-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | AANAT, HTR2C, AADAT | CRBN 671/4885IKZF3 3119/4885DDB1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.